文献速递肿瘤 PET/CT

实时机械臂辅助18F-FDG PET/CT引导经皮活检对腹部和盆腔代谢活跃病变的诊断性能

Diagnostic performance of real-time robotic arm-assisted 18F-FDG PET/CT-guided percutaneous biopsy in metabolically active abdominal and pelvic lesions.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-08-30

这项前瞻性研究纳入114例患者,评估自动机械臂辅助下18F-FDG PET/CT引导腹部和盆腔FDG高摄取病变活检的可行性和诊断性能。110例(96.5%)成功靶向并获病理诊断,54例既往CT引导活检无结论者中50例经病理确诊。灵敏度96.2%、特异度100%、阳性预测值100%、阴性预测值66.7%、准确率96.5%,未见即时并发症或迟发性危及生命事件。

要点

  • 114例中110例(96.5%)成功靶向并获病理诊断。
  • 灵敏度96.2%、特异度100%、阳性预测值100%、阴性预测值66.7%、准确率96.5%。
  • 54例既往CT引导活检无结论者中50例经病理确诊,未见即时并发症或迟发性危及生命事件。

核心结论

  • 自动机械臂辅助下经皮活检代谢活跃的腹部和盆腔病变在技术上可行、安全且准确,诊断性能高。
  • PET引导活检在患者中高度实用且有用,尤其对既往活检无结论者。

研究设计与样本

  • 前瞻性研究,纳入2014年10月至2017年12月接受PET/CT引导活检的FDG高摄取腹部和盆腔病变患者114例(男75例、女39例;平均年龄51.3±14.7岁,范围18–90岁),其中54例既往CT引导活检无结论。
  • 活检在自动机械臂辅助下完成,经PET/CT确认针尖位于目标病变内后获取实时样本,回顾组织病理学报告评估诊断性能,并以临床或影像随访确认阴性结果。

主要发现

  • 114例中110例(96.5%)成功靶向并获病理诊断,54例既往活检无结论者中50例经病理确诊。
  • 110个病变中恶性82个、良性20个、8个在治疗结束时仅见轻微残余FDG摄取且临床和影像随访至少3个月无活动性疾病。
  • 结果判定为真阳性102个、假阳性0个、真阴性8个、假阴性4个。
  • 灵敏度96.2%、特异度100%、阳性预测值100%、阴性预测值66.7%、准确率96.5%。
  • 未见即时并发症或迟发性危及生命事件。

关键数值与推荐

  • 灵敏度96.2%、特异度100%、阳性预测值100%、阴性预测值66.7%、准确率96.5%。
  • 114例中110例(96.5%)成功靶向并获病理诊断。
  • 54例既往活检无结论者中50例经病理确诊。
  • 110个病变中恶性82个、良性20个、8个治疗结束时仅见轻微残余FDG摄取且随访至少3个月无活动性疾病。
  • 真阳性102个、假阳性0个、真阴性8个、假阴性4个。

临床怎么用

  • 原文结论认为自动机械臂辅助下经皮活检代谢活跃的腹部和盆腔病变是技术上可行、安全且准确的方法,诊断性能高。
  • 原文结论认为PET引导活检在患者中高度实用且有用,尤其对既往活检无结论者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the feasibility and diagnostic performance of 18F-FDG PET/CT-guided biopsy of abdominal and pelvic lesions with automated robotic arm (ARA) assistance. METHODS: This prospective study included 114 patients (75 men, 39 women; mean age 51.3 ± 14.7 years, range: 18-90 years) who underwent PET/CT-guided biopsy of FDG-avid abdominal and pelvic lesions from October 2014 to December 2017. Of these patients, 54 had a prior inconclusive CT-guided biopsy. The biopsies were done with ARA assistance, and a real-time sample was obtained after confirming the position of the needle tip within the target lesion on PET/CT. Histopathology reports were reviewed to evaluate the diagnostic performance of the procedure. Clinical or imaging follow-up was done to confirm negative results. RESULTS: The lesions were successfully targeted in 110 of the 114 patients (96.5%) and yielded a pathological diagnosis. Pathological diagnoses were confirmed in 50 of the 54 patients with a prior inconclusive biopsy. Of the 110 lesions, 82 were malignant, 20 were benign, and 8 showed minimal residual FDG uptake at the end of treatment and had no active disease even on clinical and imaging follow-up of at least 3 months. Findings were true-positive in 102 lesions, false-positive in none, true-negative in eight and false-negative in four. The procedure showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 96.2%, 100%, 100%, 66.7 and 96.5%, respectively. No immediate complications or delayed life-threatening events were observed. CONCLUSION: Percutaneous biopsy of metabolically active abdominal and pelvic lesions with ARA assistance is a technically feasible, safe and accurate method for pathological diagnosis with high diagnostic performance. PET-guided biopsy is highly practical and useful in patients, especially in those with a previous inconclusive biopsy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kumar R, Mittal BR, Bhattacharya A, et al. Diagnostic performance of real-time robotic arm-assisted 18F-FDG PET/CT-guided percutaneous biopsy in metabolically active abdominal and pelvic lesions. Eur J Nucl Med Mol Imaging. 2018. PMID: 30167803. doi:10.1007/s00259-018-4133-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。